ReviewInternational journal of molecular sciences2021
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Real‑life diagnostic and therapeutic approach to CLL/SLL in tuscany: the 2025 consensus.Clinical and experimental medicine · 2026Guideline
- CAR-T Cell Therapy: Pioneering Immunotherapy Paradigms in Cancer Treatment.Current pharmaceutical biotechnology · 2026Review
- CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions.Medical oncology (Northwood, London, England) · 2025Review
- Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia.Discover oncology · 2025Review
- Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.International journal of hematology-oncology and stem cell research · 2025Review
- Chimeric Antigen Receptor-T Cells in the Modern Era of Chronic Lymphocytic Leukemia Treatment.Cancers · 2025Review
- The importance ofMolecular biology research communications · 2025Review
- Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.Medical oncology (Northwood, London, England) · 2024Review
- Review
- Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.Clinical and experimental medicine · 2023Review
- Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.Science China. Life sciences · 2023Article
- Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy.Doklady. Biochemistry and biophysics · 2023Article
- Depletion of polyfunctional CD26Experimental hematology & oncology · 2023Article
- Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs).International journal of molecular sciences · 2022Review
- Switchable targeting of solid tumors by BsCAR T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.Blood advances · 2022Article
- Article
- Chemoimmunotherapy Administration Protocol Design for the Treatment of Leukemia through Mathematical Modeling and In Silico Experimentation.Pharmaceutics · 2022Article
- CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.Current oncology (Toronto, Ont.) · 2022Review
- [Preparation of CD52-targeted chimeric antigen receptor-modified T cells and their anti-leukemia effects].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.